Shares of Horizon Pharma PLC (NASDAQ:HZNP) ended Monday session in green amid volatile trading. The shares closed up +0.26 points or 1.37% at $19.17 with 1.89 million shares getting traded. Post opening the session at $18.91, the shares hit an intraday low of $18.66 and an intraday high of $19.25 and the price vacillated in this range throughout the day. The company has a market cap of $3.04 billion and the numbers of outstanding shares have been calculated to be 160.90 million shares.
On Sept. 12, 2016 Horizon Pharma plc (HZNP) and Raptor Pharmaceutical Corp. (RPTP) announced the companies have entered into a definitive agreement under which Horizon Pharma will acquire all of the issued and outstanding shares of Raptor Pharmaceutical Corp. common stock for $9.00 per share in cash, for an implied fully diluted equity value of approximately $800 million. The transaction is expected to close in the fourth quarter of 2016.
“The proposed acquisition of Raptor furthers our commitment to helping people with rare diseases and is a significant step in advancing our strategy to expand our rare disease business,” said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. “Along with the potential for accelerated revenue growth, the addition of Raptor strengthens our U.S. orphan business and provides a platform to expand our orphan business in Europe and other key international markets. We look forward to working with new patient communities and building on the success of the Raptor team.”
Shares of Express Scripts Holding Company (NASDAQ:ESRX) ended Monday session in green amid volatile trading. The shares closed up +0.40 points or 0.58% at $69.65 with 3.40 million shares getting traded. Post opening the session at $69.25, the shares hit an intraday low of $68.96 and an intraday high of $69.80 and the price vacillated in this range throughout the day. The company has a market cap of $43.64 billion and the numbers of outstanding shares have been calculated to be 630.22 million shares.
Express Scripts Holding Company (ESRX) on Aug. 31, 2016 launch of its Diabetes Care Value Program℠, the industry’s most comprehensive approach to improve pharmacy care while controlling plan costs for people with diabetes.
The new program – part of the Express Scripts SafeGuardRx℠ suite of pharmacy solutions – combines a novel quality-based pharmacy network, a holistic approach to diabetes patient care and cost management, and financial guarantees that will significantly reduce participating plans’ anticipated increase in diabetes-drug spend for 2017.
“Diabetes is wreaking havoc on patients, and it is also a runaway driver of cost for payers,” said Glen Stettin, MD, Senior Vice President and Chief Innovation Officer at Express Scripts. “Our Diabetes Care Value Program helps our clients and diabetes patients prevail over the cost and care challenges created by this terrible disease.”